Literature DB >> 1607705

Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989.

S E Holm1, A Norrby, A M Bergholm, M Norgren.   

Abstract

Serotypes of serious, sometimes fatal, streptococcal infections in Sweden during 1988-1989 were analyzed. The T1M1 type totally dominated, representing almost 70% of all group A streptococci from serious and uncomplicated infections at the peak of the outbreak. Immunoblots of isolates from various patient groups showed that all isolates produced high amounts of erythrogenic toxin (ET) B and high amounts of ET-C, whereas ET-A was released only in small amounts and from few isolates. ELISAs showed high antibody levels to these toxins and to the M1 antigen in patients with uncomplicated infections. Low antibody levels against M1 were seen in patients with bacteremia and in fatal cases; the latter also had low antibody levels against ET-B. It seems likely that a combination of production of large amounts of toxin and low antibody titers to it and to the M antigen of the infecting isolate are determining factors for the outcome of the infection. No signs of primary immune deficiency were noted.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1607705     DOI: 10.1093/infdis/166.1.31

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  86 in total

1.  Toxoids of streptococcal pyrogenic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome.

Authors:  M Roggiani; J A Stoehr; S B Olmsted; Y V Matsuka; S Pillai; D H Ohlendorf; P M Schlievert
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

2.  M types of group a streptococcal isolates submitted to the National Centre for Streptococcus (Canada) from 1993 to 1999.

Authors:  Gregory J Tyrrell; Marguerite Lovgren; Betty Forwick; Nancy P Hoe; James M Musser; James A Talbot
Journal:  J Clin Microbiol       Date:  2002-12       Impact factor: 5.948

Review 3.  Extracellular enzymes with immunomodulating activities: variations on a theme in Streptococcus pyogenes.

Authors:  Mattias Collin; Arne Olsén
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

4.  Role of RopB in growth phase expression of the SpeB cysteine protease of Streptococcus pyogenes.

Authors:  Melody N Neely; William R Lyon; Donna L Runft; Michael Caparon
Journal:  J Bacteriol       Date:  2003-09       Impact factor: 3.490

5.  Molecular analysis of group A streptococcal isolates associated with scarlet fever in southern Taiwan between 1993 and 2002.

Authors:  Jing-Jou Yan; Ching-Chuan Liu; Wen-Chien Ko; Shui-Yuan Hsu; Hsiu-Mei Wu; Yee-Shin Lin; Ming T Lin; Woei-Jer Chuang; Jiunn-Jong Wu
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

6.  Reciprocal, temporal expression of SpeA and SpeB by invasive M1T1 group a streptococcal isolates in vivo.

Authors:  S U Kazmi; R Kansal; R K Aziz; M Hooshdaran; A Norrby-Teglund; D E Low; A B Halim; M Kotb
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

7.  Absence of SpeB production in virulent large capsular forms of group A streptococcal strain 64.

Authors:  R Raeder; E Harokopakis; S Hollingshead; M D Boyle
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

8.  Streptococcal pyrogenic exotoxin B-induced apoptosis in a549 cells is mediated by a receptor- and mitochondrion-dependent pathway.

Authors:  Wan-Hua Tsai; Chia-Wen Chang; Woei-Jer Chuang; Yee-Shin Lin; Jiunn-Jong Wu; Ching-Chuan Liu; Wen-Tsan Chang; Ming T Lin
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

Review 9.  Toward a genome-wide systems biology analysis of host-pathogen interactions in group A Streptococcus.

Authors:  James M Musser; Frank R DeLeo
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

10.  Superantigenic properties of the group A streptococcal exotoxin SpeF (MF).

Authors:  A Norrby-Teglund; D Newton; M Kotb; S E Holm; M Norgren
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.